Document is current

Any future updates will be listed below

Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study

Crossref DOI link: https://doi.org/10.1007/s12032-015-0580-4

Published Online: 2015-03-19

Published Print: 2015-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark